A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma by Takuji Okusaka et al.
PHASE II STUDIES
A randomized phase II trial of intra-arterial chemotherapy
using SM-11355 (Miriplatin) for hepatocellular carcinoma
Takuji Okusaka & Hiroshi Kasugai & Hiroshi Ishii &
Masatoshi Kudo & Michio Sata & Katsuaki Tanaka &
Yasukazu Shioyama & Kazuaki Chayama &
Hiromitsu Kumada & Masaharu Yoshikawa &
Toshihito Seki & Hidetugu Saito & Naoaki Hayashi &
Keiko Shiratori & Kiwamu Okita & Isao Sakaida &
Masao Honda & Yukio Kusumoto & Takuya Tsutsumi &
Kenji Sakata
Received: 10 October 2011 /Accepted: 27 November 2011 /Published online: 21 December 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Background SM-11355 is a platinum complex
developed to treat hepatocellular carcinoma (HCC) via ad-
ministration into the hepatic artery as a sustained-release
suspension in iodized oil. We conducted a multicenter phase
II trial in patients with HCC to evaluate the efficacy and
safety of SM-11355, using a Zinostatin stimalamer
suspension in iodized oil as a reference. Methods Patients
with unresectable HCC were randomized 2:1 to receive
administration of the SM-11355 or Zinostatin stimalamer
suspension into the hepatic artery. A second injection was
given 4–12 weeks later. Efficacy was evaluated by CT
3 months after treatment and categorized as therapeutic
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effect (TE) V to I, where TE V was defined as disappearance
or 100% necrosis of all treated tumors. Results A total of
122 patients were evaluated for efficacy and toxicity (SM-
11355, n083; Zinostatin stimalamer, n039). Baseline char-
acteristics were similar in the two groups. The TE V rates
were 26.5% (22/83) and 17.9% (7/39) in the SM-11355 and
Zinostatin stimalamer groups, respectively. In the SM-
11355 group,the most frequent drug-related adverse events
(AEs) of≥grade 3 were elevated AST, elevated ALT, throm-
bocytopenia, and hyperbilirubinemia. The AEs with the
largest difference between the two groups (SM-11355 vs.
Zinostatin stimalamer) were hepatic vascular injury (0 vs.
48.4%) and eosinophilia (84.3 vs. 41.0%). The 2-year and 3-
year survival rates were 75.9% vs. 70.3% and 58.4% vs.
48.7%, respectively. Conclusions The results suggest that
SM-11355 in iodized oil has similar efficacy to Zinostatin
stimalamer and that repeated dosing of SM-11355 is possi-
ble without hepatic vascular injury in cases of relapse.
Keywords Iodized oil . MIRIPLA . Liver cancer .
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Introduction
International cancer statistics from 2002 indicate that hepa-
tocellular carcinoma (HCC) ranks third behind lung and
gastric cancer in the number of deaths [1]. The impact of
current standard treatments for advanced HCC, including
conventional transcatheter arterial chemoembolization
(TACE) using doxorubicin or cisplatin is limited and the
prognosis is unsatisfactory [2]. Therefore, there is a clear
need for new treatments in management of this disease.
SM-11355, (SP-4-2)-[(1R,2R)-cyclohexane-1,2-diamine-
N,N’]bis (tetradecanoato-O) platinum monohydrate (Fig. 1)
is a highly lipophilic platinum derivative that can be deliv-
ered suspended in iodized oil, an oily lymphographic agent,
via injection into the hepatic artery [3]. Following injection
into an HCC-feeding artery, iodized oil selectively accumu-
lates in the tumor. Similarly, an iodized oil suspension of
SM-11355 accumulates selectively within HCC nodules,
allowing continuous release of active platinum compounds
into tumor tissues. A phase I dose-finding study using
different injection levels indicated a recommended dose of
20 mg/mL and an upper limit of the injection volume of
6 mL [4]. In an early phase II trial , SM-11355 showed a
promising anticancer effect with a mild toxicity profile in
patients with advanced HCC. Responses were evaluated by
computed tomography (CT) three months after treatment,
with complete response (CR) defined as disappearance or
100% necrosis of all tumors. Iodized oil accumulation in
tumors was taken to indicate necrosis. Of 16 eligible
patients, 9 (56%) showed CR [5]. This CR rate was superior
to our expectation, because the CR rate in conventional
TACE is 15–20% based on the same evaluation criteria [6,














Fig. 1 Structural formula of SM-11355
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indicated that SM-11355 has potential as an alternative to
TACE in treatment of advanced HCC.
Based on these findings, we conducted a late phase II
open-label trial of SM-11355. The aims of the study were to
re-evaluate the efficacy, safety and pharmacokinetics of SM-
11355 in a larger population, since only 16 eligible patients
were included in the previous phase II study, and to confirm
the candidacy of SM-11355 as an experimental treatment in
a forthcoming clinical study in comparison with conven-
tional TACE. To achieve regulatory approval of SM-11355
in Japan, it was necessary to undertake a parallel study.
Therefore, we conducted a randomized phase II trial using
Zinostatin stimalamer as a reference, because this agent is
the only commercially available lipophilic drug for HCC in
Japan and chemolipiodolization of Zinostatin stimalamer
has been approved for treatment of advanced HCC in Japan
[8, 9]. However, statistical comparisons between the two
treatment groups were not planned since the goal of the
study was re-evaluation of outcomes for SM-11355, and
because the sample size required to conduct a statistical
analysis was larger than expected.
Patients and methods
Inclusion criteria
Consecutive patients with HCC were eligible for the study if
they had no indication for resection or local ablation thera-
py. The diagnosis was confirmed histologically and/or clin-
ically using angiography and enhanced CT. Each patient
was required to meet the following criteria: at least one
measurable intrahepatic lesion that showed tumor staining
by CT; tumor stage II or III in the staging system of the
Liver Cancer Study Group of Japan [6, 7]; Child-Pugh
classification A or B; adequate hematological function
(WBC≥3000 /μL, blood platelets≥50000 /μL, hemoglo-
bin≥9.5 g/dL), adequate hepatic function (AST and ALT≤
5-fold the upper limit of normal, serum bilirubin <3 mg/dL,
serum albumin≥3 g/dL), adequate renal function (serum
creatinine≤ the upper limit of normal); an Eastern Coopera-
tive Oncology Group performance status of 0–2; age 20 to
74 years old; minimum life expectancy≥3 months, and
provision of written informed consent. Patients who had
undergone hepatic resection, local ablation therapy, and/or
TACE were eligible if they showed no evidence of local
tumor recurrence in the treated lesions. Patients who had
undergone chemolipiodolization with anti-cancer agents
other than Zinostatin stimalamer or a platinum-containing
agent were also eligible if the treated lesions were resected.
The previous anticancer treatment had to have been discon-
tinued for at least 4 weeks before enrollment in this study.
Exclusion criteria
Patients were excluded if they met any of the following
criteria: history of allergy to iodine-containing agents and/
or contrast material; history of systemic chemotherapy; se-
rious complication such as a cardiac disease or a thyroid
disease ; concomitant malignancy; bile duct invasion; preg-
nant or lactating women and fertile patients who were not
using effective contraception; and participation in another
trial within 6 months before giving informed consent.
Study treatment
Patients who met the entry criteria were provisionally reg-
istered and randomly assigned to the SM-11355 or Zinosta-
tin stimalamer group before undergoing angiography. Each
investigator then confirmed registration after establishing
that the patient met the following additional requirements
based on angiographic findings: intrahepatic lesions that
showed tumor staining and were fed by an artery with an
appropriate structure for catheter insertion; no evidence of
tumor thrombus in the portal or hepatic vein; no evidence of
intrahepatic arteriovenous shunting; and no evidence of
local tumor recurrence in previously treated lesions. The
central random assignment by dynamic allocation to either
a SM-11355 group or Zinostatin stimalamer group was
stratified according to center and maximun tumor diameter.
A suspension of SM-11355 (MIRIPLA; Dainippon Sumi-
tomo Pharma Co., Japan) or Zinostatin stimalamer
(SMANCS; Astellas Pharma Inc., Japan) in iodized oil was
injected into the hepatic artery using Seldinger’s technique.
Patients in the SM-11355 group received SM-11355 sus-
pended in iodized oil (20 mg/mL) in a volume of up to
6 mL according to tumor size. Patients in the Zinostatin
stimalamer group received Zinostatin stimalamer suspended
in iodized oil (1mg titer/mL) in a volume of up to 6mL.When
iodized oil accumulation in the treated tumor was insufficient
and tumor staining was found in diagnostic imaging 5 weeks
(±10 days) after the first injection, a second injection was
given within 12 weeks after the first injection.
Efficacy and safety assessment
The antitumor effect was evaluated by CT or MRI 3 months
after the last injection according to the response criteria
proposed by the Liver Cancer Study Group of Japan [10],
which are similar to the criteria proposed by the European
Association for the Study of the Liver (EASL) Panel of
Experts on HCC [11]. Tumor size was measured using the
sum of the products of the perpendicular longest diameters
of all measurable lesions. In the response evaluation criteria,
iodized oil accumulation in a tumor is regarded as an indi-
cation of necrosis because significant positive correlations
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have been reported between iodized oil accumulation ob-
served on CT images and necrotic regions in resected
tumors examined pathologically after TACE and after
intra-arterial chemotherapy with iodized oil [5, 8, 12, 13].
Therapeutic effect (TE) was defined as follows: TE V,
disappearance or 100% necrosis of all treated tumors; TE
IV, more than 50% reduction in tumor size and/or more than
50% necrosis; TE III, more than 25% reduction in tumor
size and/or more than 25% necrosis; and TE I, more than
25% increase in tumor size regardless of the necrotic effect.
TE II was defined as a response not qualifying for classifi-
cation as TE V, IV, III, or I. When a patient assigned to the
SM-11355 group and judged to be TE V developed a tumor
in a different region and requested SM-11355, the drug was
given continuously after the study, provided that this was
felt to be necessary by the investigator. The primary end-
point was the TE V rate. The secondary endpoints were the
response rate based on the Response Evaluation Criteria in
Solid Tumors (RECIST) and on the Japan Society for Can-
cer Therapy Criteria [14], which are similar to the World
Health Organization (WHO) Criteria. The serum α-
fetoprotein (AFP) level of each patient was measured before
and 5 weeks after each treatment. Survival was evaluated using
the Kaplan-Meier method. Toxicity was assessed according to
the criteria of the Japan Society for Cancer Therapy [15],
which are also fundamentally similar to WHO criteria.
Pharmacokinetics
Pharmacokinetic data were determined in patients in the
SM-11355 group who gave written informed consent and
were treated at institutions where a pharmacokinetic study
could be conducted. Peripheral blood samples (5 ml) were
collected 3 weeks after each treatment for determination of
the total plasma platinum concentration and the platinum
concentration in methanol extracts (SM-11355 metabolite
concentration). The total platinum concentration in resected
tissue was also determined in a patient who underwent
surgery after evaluation of efficacy.
Statistical analysis
We anticipated enrollment of 120 patients at 17 participating
hospitals over the study period of 3 years. A 2:1 ratio for
SM-11355 to Zinostatin stimalamer randomization was cho-
sen as a balance between the goals of the study, which were
to re-evaluate the efficacy, safety and pharmacokinetics of
SM-11355 in a larger population than that in the previous
phase II study, and the current limited use of Zinostatin
stimalamer. The number of subjects was determined based
on the feasibility of the study because the sample size
required to conduct a statistical analysis was larger than
expected. Assuming a baseline 15% TE V rate for
conventional TACE [6], the SM-11355 arm would be con-
sidered ‘favorable’ if there was a 10% improvement in this
endpoint (to 25%) with an acceptable toxicity profile. A
total of 80 patients in the SM-11355 arm is needed to
estimate the TE-V rate with an accuracy of ±10%.
This study was not powered to permit formal statistical
comparison between the two treatment arms. However, it
does allow an initial assessment of SM-11355 in terms of
TE-V, response rate, overall survival and toxicity with a
view to performance of a follow-on phase III study.
Results
Patient
From April 2002 to October 2004, 131 patients were enrolled
in the study, and 126 were assigned randomly at a 2:1 ratio to
receive SM-11355 (85 patients) or Zinostatin stimalamer (41
patients) (Fig. 2). Five patients were excluded from the ran-
domization because tumor staining was not observed in angi-
ography and/or an appropriate hepatic artery for selective
catheter insertion was not found (n03), multiple tumors were
observed in angiography that required reconsideration of the
treatment strategy (n01), and withdrawal of consent (n01).
After administration, 4 patients were identified as ineligible
due to a platelet count <50,000/μL (n01), esophageal cancer
(n01) in the SM-11355 group, and deviation from correct use
of the investigational products (n02) in the Zinostatin stim-
alamer group. Therefore, 122 patients (SM-11355 group, n0
83; Zinostatin stimalamer group, n039) were analyzed for
efficacy and safety. The baseline demographic and disease
characteristics of the patients are listed in Table 1.
Of the 85 original patients in the SM-11355 group, 18
were withdrawn from the study before the planned evalua-
tion of efficacy 3 months after the first injection because of
marked progression of the primary disease (n05), serious
adverse events (n04), use of prohibited concomitant thera-
peutic agents or a requirement for combination therapy (n0
3), and other reasons (duplicated count). Treatment was
terminated in 11 patients after evaluation of the the first
injection because complete necrosis of tumors (TE V) was
obtained. The remaining 56 patients received a second
injection.
Of the 41 patients in the Zinostatin stimalamer group, 9
were withdrawn before the planned evaluation of efficacy
3 months after the first injection, due to marked progression
of the primary disease (n02), serious adverse events (n01),
contravention of the protocol (n01), appearance of hepatic
injury (n01), and other reasons (duplicated count). Treatment
was terminated in 7 patients after evaluation of the first injec-
tion because complete necrosis of tumors (TEV)was obtained.
The remaining 25 patients received a second injection.
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131 patients enrolled
Excluded (n=5)
Did not meet inclusion criteria (n=4)
Withdrawal of consent (n=1)
Randomized (n=126)
SM-11355 group (n=85) Zinostatin stimalamer group (n=41)
Allocated to intervention (n=85)
Received allocated intervention (n=85)
Did not receive allocated intervention (n=0) 
Discontinued intervention (n=41)
Lost to follow-up after discontinuation of intervention (n=0)
Analyzed (n=83)
Excluded from analysis (n=2)*
Allocated to intervention (n=41)
Received allocated intervention (n=41)
Did not receive allocated intervention (n=0) 
Analyzed (n=39)
Excluded from analysis (n=2)*
Discontinued intervention (n=85)




















The second injection was given to 56 patients in the SM-11355 
group and to 25 patient in the Zinostatin stimalamer group
*Two of the patients each in the both groups were excluded from 
the full analysis set defined in the protocol. Refer to patient 
characteristics in results.
Fig. 2 Study flow diagram
Table 1 Patient background
SM-11355 Zinostatin stimalamer
Number of patients 83 39
Sex (male:female) 70:13 (84.3%:15.7%) 30:9 (76.9%:23.1%)
Age (median) 67.0 (48–74) 68.0 (52–74)
PS (0:1:2:3:4) 80:3:0:0:0 35:4:0:0:0
HBs antigen positive 9 (13.6%) 1 (3.2%)
HCV antibody positive 55 (83.3%) 30 (96.8%)
HBs antigen · HCV antibody positive 2 (3.0%) 0 (0%)
Tumor stage (I:II:III:IV-A:IV-B) 0:43:40:0:0 0:19:20:0:0
Child-Pugh Classification (A:B:C) 61:22:0 32:7:0
Previously treated 25 (30.1%) 13 (33.3%)
Number of tumors 1 24 (28.9%) 9 (23.1%)
2 19 (22.9%) 11 (28.2%)
3 16 (19.3%) 7 (17.9%)
≥4 24 (28.9%) 12 (30.8%)
Maximum tumor diameter (mm) (Min-Max) 29.0 (10.0–80.0) 29.0 (10.0–94.0)
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Efficacy
The antitumor efficacy is shown in Table 2. The percentages
of TE V patients were 26.5% (22/83) [95% confidence
interval (CI): 17.4–37.3%] in the SM-11355 group and
17.9% (7/39) [95% CI: 7.5–33.5%] in the Zinostatin stim-
alamer group. In a RECIST assessment, response rates were
24.1% (20/83) [95% CI: 15.4–34.7%] and 25.6% (10/39)
[95% CI: 13.0–42.1%] in the respective groups. Based on
the Japan Society for Cancer Therapy Criteria, the tumor
responses were 20.5% (17/83) [95% CI: 12.4–30.8%] and
23.1% (9/39) [95% CI: 11.1–39.3%] in the respective
groups (Table 2).
Of 61 patients with a pre-treatment AFP level above the
upper limit of normal in the SM-11355 group, 6 / 60 (10%)
had an AFP level within the normal range 5 weeks after the
first injection. No data for the AFP level were available for 1
patient in the SM-11355 group at 5 weeks after the first
injection. Among the 61 patients, 37 received a second
injection and 6 (16%) had a normal AFP level 5 weeks after
the second injection. Of the 26 patients in the Zinostatin
stimalamer group with a pre-treatment AFP level above the
upper limit of normal, none had an AFP level within the
normal range 5 weeks after the first injection. Among the 26
patients, 18 received a second injection, but none had a
normal AFP level 5 weeks after the second injection.
Cumulative survival rates are shown in Fig. 3. The
follow-up period was approximately 3 years after the treat-
ment period. The longest follow-up periods in the SM-
11355 and Zinostatin stimalamer groups were both 5.6 years,
and the median periods were 3.0 years and 2.8 years, re-
spectively. The one-year survival rates in the SM-11355 and
Table 2 Antitumor efficacy
Group N Antitumor efficacy
“Criteria for Evaluation of Direct Effects on Hepatocellular Carcinoma” of the Liver Cancer Study Group of Japan
V IV III II I NE Percentage of TE V (%) [95% CI]
SM-11355 83 22 21 12 7 17 4 26.5 [17.4–37.3]
Zinostatin stimalamer 39 7 14 4 10 1 3 17.9 [7.5–33.5]
Response Evaluation Criteria in Solid Tumors (RECIST)
CR PR SD PD NE Percentage of CR + PR
SM-11355 83 0 20 52 10 1 24.1 [15.4–34.7]
Zinostatin stimalamer 39 0 10 23 6 0 25.6 [13.0–42.1]
“Clinical Response Evaluation Criteria for Solid Tumor Chemotherapy” of the Japan Society for Cancer Therapy
CR PR MR NC PD NE Percentage of CR + PR
SM-11355 83 0 17 10 36 19 1 20.5 [12.4-30.8]
Zinostatin stimalamer 39 0 9 5 19 6 0 23.1 [11.1–39.3]
80 70 65 59 47 42 30 18 13 6 1 0



























Fig. 3 Cumulative survival rate
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Zinostatin stimalamer groups were 90.1% and 97.4%, the 2-
year survival rates were 75.9% and 70.3%, respectively, and
the 3-year survival rates were 58.4% and 48.7%, respective-
ly. The median survival time (MST) was 3.7 years in the
SM-11355 group and 2.8 years in the Zinostatin stimalamer
group.
Safety
Hematological adverse events were relatively mild and tran-
sient in both groups (Table 3). The incidences of neutrope-
nia and decreased hemoglobin were similar in the two
groups, but the incidence of eosinophilia was higher in the
SM-11355 group, and the incidences of leukopenia and
thrombocytopenia were higher in the Zinostatin stimalamer
group. Most non-hematological adverse events (Table 3)
were also mild and transient in both groups. Major events
of grade 3 or higher involved liver dysfunction (including
elevations in AST, ALT and hyperbilirubinemia) and
hyperglycemia, but these had similar incidences in both
groups and most were reversible.
One patient in the SM-11355 group died of esophageal
variceal rupture, which occurred 12 days after the first injec-
tion, and one patient in the Zinostatin stimalamer group died
of hepatic failure 168 days after the second injection. Esoph-
ageal variceal rupture was considered not to be related to the
treatment because the condition was recognized before initia-
tion of treatment and the event was not classified as a toxicity.
Other serious adverse events occurred in 8 patients in the SM-
11355 group (increase in AST in 2 patients; and increase in
ALT, sepsis, systemic inflammatory response syndrome
(SIRS: a syndrome characterized by systemic inflammation
and extensive tissue damage associated with serious infec-
tion), decrease in neutrophils, acute myocardial infarction
(AMI), and hypotension in 1 case each) and in 2 patients in
the Zinostatin stimalamer group (respiratory distress and ar-
rhythmia, and abdominal pain in 1 case each). All the patients
recovered with appropriate treatment. Most of these events
Table 3 Hematological and non-hematological adverse events
SM-11355 Zinostatin stimalamer
No. of patients All (%) ≥ Grade 3 (%) No. of patients All (%) ≥ Grade 3 (%)
Decrease in leukocytes 83 41.0 1.2 39 66.7 0
Decrease in lymphocytes 83 79.5 0 39 79.5 0
Decrease in neutrophils 83 53.0 8.4 39 43.6 2.6
Decrease in platelets 83 50.6 12.0 39 74.4 10.3
Decrease in hemoglobin 83 15.7 0 39 10.3 0
Increase in eosinophils 83 84.3 0 39 41.0 0
Increase in monocytes 83 57.8 0 39 76.9 0
Fatigue 83 39.8 0 39 46.2 0
Fever 83 96.4 3.6 39 97.4 0
Chills 83 39.8 0 39 51.3 0
Vomiting 83 55.4 1.2 39 51.3 0
Pain at injection site 83 43.4 0 39 41.0 2.6
Decrease in albumin 83 50.6 0 39 28.2 0
Increase in ALP 83 30.1 1.2 39 51.3 0
Increase in ALT 83 59.0 24.1 39 66.7 20.5
Increase in AST 83 62.7 26.5 39 79.5 38.5
Increase in bilirubin 83 57.8 12.0 39 71.8 5.1
Decrease in calcium 83 38.6 0 39 51.3 0
Increase in γ-GTP 83 49.4 0 39 61.5 0
Increase in glycemia 83 56.6 12.0 39 56.4 5.1
Increase in LDH 83 60.2 0 39 69.2 0
Increase in CRP 83 95.2 0 39 79.5 0
Prolonged PT time 83 42.2 1.2 39 28.2 0
Decrease in urinary creatinine 83 54.2 0 39 56.4 0
Increase in urinary creatinine 83 49.4 0 39 38.5 0
Increase in urinary NAG 83 89.2 0 39 87.2 0
Adverse events that occurred at a rate of >40% are shown
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were considered to be probable or possible drug-related tox-
icities, except for the cases of SIRS and AMI in the SM-11355
group. SIRS was judged to have no association with the
investigational drug based on the results of blood culture
and changes in test values. This patient was treated using a
urinary catheter, and urinary tract infection is a cause of SIRS.
A similar judgment was made for the case of AMI based on
the chronological relationship between drug administration
and the onset of disease.
In the subsequent angiographic examination before the
second administration of SM-11355 or Zinostatin stima-
lamer or in postprotocol treatment, hepatic artery damage
that was probably due to intra-arterial drug administration
was observed in 15/31 (48.4%) patients, shunt occurred in 5/
31 (16.1%), and disorders of the hepatobiliary system were
observed in 3/39 (7.7%) in the Zinostatin stimalamer group.
None of these events were observed in patients in the SM-
11355 group. Grade 3 hepatic artery damage and a grade 4
disorder of the hepatobiliary system were observed in 1 case
each in the Zinostatin stimalamer group. Hepatobiliary dam-
age that may have been caused by arterial damage was
found in 3 patients in the Zinostatin stimalamer group (1
case each of liver atrophy and bile duct dilatation, bile duct
necrosis, and liver failure and bile duct stricture), whereas
there were no such findings in the SM-11355 group.
In the SM-11355 group, the percentages of patients with an
increase in Child-Pugh score of one or more points compared
to the pre-administration score were 27.7% (23/83) and 17.9%
(10/56) in the 5 weeks after the 1st administration and the
5 weeks after the 2nd administration, respectively. In the
Zinostatin stimalamer group, these percentages were 35.9%
(14/39) and 50.0% (12/24), respectively (Fig. 4).
Pharmacokinetics
Total plasma platinum concentrations and platinum concen-
trations in methanol extracts (Table 4) were determined in 30
and 24 patients in the SM-11355 group who were given one
and two injections, respectively, and received median doses of
85 (Min-max: 24–120) and 120 (10–120) mg, respectively.
The mean total platinum concentrations after the first and
second injections were 9.6 and 12.9 ng/mL, respectively,
and the mean percentages of the concentration in methanol
extracts relative to the total plasma platinum concentration
were 12.2% and 9.8% after the first and second injections,
respectively. In one patient who underwent surgery 172 days
after the second injection, the total platinum concentration was
determined in the resected liver tissue. The total dose was
200mg (first injection: 100mg; second injection: 100mg) and
the concentration in the tumor region of sample S6, which had
a 10% necrotic effect, was 62,000 ng/g tissue and that in the
non-tumor region was 22,000 ng/g tissue. In contrast, the
concentration in the tumor region of sample S8, which
showed 50% necrosis, was 260,000 ng/g tissue and that in
the non-tumor region was 67,000 ng/g tissue.
Discussion
Most anticancer agents used in TACE are water-soluble and
inappropriate for suspension in iodized oil, and are usually
administered as a water-in-oil emulsion. Consequently, these
agents have reduced sustained release due to poorer retention
in the tumor, leading to a limited antitumor effect and adverse
effects caused by diffusion of the agents into the blood [16]. In
contrast, lipophilic anticancer agents have a high affinity for
iodized oil and those injected into the hepatic artery with
iodized oil are retained selectively in tumors and exert contin-
uous antitumor effects. SM-11355 is a structurally modified
platinum complex with improved affinity for iodized oil due
to increased lipophilicity [3]. In an AH109A-transplanted rat
liver tumor model, the platinum concentration in the tumor
was sustained for longer following administration of a iodized
oil suspension of SM-11355 compared to a suspension of
cisplatin, with SM-11355 distributed in tumor tissues more
selectively than cisplatin [17]. Phase I and early phase II trials
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Fig. 4 Changes in Child-Pugh Classification
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of SM-11355 have also shown that the total plasma platinum
concentration is much lower than that with cisplatin [4, 5, 18].
Our pharmacokinetic data verify these results and suggest that
SM-11355 is retained in liver tumors selectively and exerts a
continuous effect on the tumor.
In patients in whom the total plasma platinum concentration
and the platinum concentration in methanol extracts were
determined after the first and second injections, the platinum
concentration in methanol extracts 3 weeks after injection
(estimated to be the peak of the total plasma platinum concen-
tration) was approximately 10% of the total plasma platinum
concentration. Of the platinum components released from the
SM-11355 suspension and transferred into the systemic circu-
lation, some are irreversibly bound to plasma proteins and are
no longer bioactive. After exclusion of these components, the
amount remaining in the plasma is estimated to be up to about
10% of the dose. The total platinum concentrations in several
regions of the liver were also determined in one patient. The
concentrations in tumors regionswere significantly higher than
those in non-tumor regions and several thousand-fold higher
than the mean total plasma platinum concentration at 3 weeks
±3 days after the second injection (12.9 ng/mL). The total
platinum concentration was also higher in tissues in which a
higher antitumor effect was observed.
The results of the efficacy re-evaluation suggested that SM-
11355 has a similar effect to that of Zinostatin stimalamer
following injection of an iodized oil suspension of each drug
into the hepatic artery. The primary endpoint (TE V rate based
on the Criteria for Evaluation of Direct Effects on Hepatocel-
lular Carcinoma) and the secondary endpoint (response rate
based on the Japan Society for Cancer Therapy Criteria and
RECIST) in the SM-11355 group were almost the same as
those in the Zinostatin stimalamer group. However, the per-
centage of TE V cases in the SM-11355 group (26.5% [17.4–
37.3%]) in this trial was lower than the value of 56% [30–
80%] found in the early phase II trial. The discrepancy in the
percentage of TE V cases may be due to differences in the
tumor burden in the two trials. Eleven (68.8%) of 16 patients
in the early phase II study had 3 or less tumors and a longest
tumor diameter of 3 cm or less, whereas only 38 (45.8%) of 83
patients in the late phase II study had these characteristics.
The major toxicities of grade 3 or higher involved liver
dysfunction, including increases in AST, ALT and bilirubin,
and a decrease in platelets in both groups. The incidences
were similar in each group and most of the effects were
reversible. An increase in eosinophils was found in 84.3%
of patients in the SM-11355 group, and was considered to be
a SM-11355-specific adverse event. The precise mechanism
is unknown, but the finding was not thought to indicate
anaphylaxis because the increase in eosinophils showed no
marked correlation with an increase in IgE and/or allegic
symptoms like wheezing. Renal disorder was transient in
patients of the SM-11355 group, except for a patient with
sepsis. The incidences and severity of increased blood cre-
atinine and positive urine protein in the SM-11355 group
were higher than the respective levels in the Zinostatin
stimalamer group (9/83, 10.8% vs. 2/39, 5.1%; and 22/83,
26.5% vs. 2/39, 5.1%, respectively). Based on these data,
we consider that the patients were thoroughly followed up.
Injection of SM-11355 did not lead to local vascular damage
and had fewer irreversible effects on the hepatobiliary system
compared with Zinostatin stimalamer. Zinostatin stimalamer
has been reported to have major safety problems, including
hepatic arterial damage and effects on the hepatobiliary system
that are irreversible and prevent repeated treatment [5, 19, 20]
Therefore, SM-11355 may be advantageous for frequent re-
peated treatment and maintenance of liver function. The
changes in Child-Pugh Class indicated a low incidence of
treatment-induced hepatic dysfunction in the SM-11355 group.
Based on the results of this trial, we conclude that SM-
11355 in iodized oil has similar efficacy to that of Zinostatin
stimalamer, which is the only drug currently approved for
chemolipiodolization for HCC in Japan. The TE V rate of
26.5% in the SM-11355 group was considered ‘favorable’
Table 4 Blood drug concentrations
Administration frequency Once Twice
Dose (mg) Number of patients 30* 24*
Median (Min-Max) 85.0 (24–120) 120.0 (10–120)
Total plasma platinum concentration (ng/mL) Number of patients 30 24
Mean 9.6 12.9
SM-11355 metabolite concentration in methanol extracts (ng/mL) Number of patients 32 24
Mean 1.17 1.19
[SM-11355 in methanol-extracted fraction*] /
[total plasma platinum concentration] × 100 (%)
Number of patients 30 24
Mean 12.2 9.8
Number of subjects in whom both the total plasma platinum concentration and SM-11355 metabolite concentration in methanol extracts were measured
* Methanol-extracted fraction: The fraction of SM-11355-derived substances includes components that may exert therapeutic activity as an
anticancer agent and excludes components that are irreversibly bound to plasma protein
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based on our assumption of a TE V rate of 15% for conven-
tional TACE before the initiation of this study, and was equiv-
alent or superior to the rate of about 20% found in patients
receiving current standard TACE treatment in a recent report
[7]. Our results also suggest that repeated dosing of SM-11355
in iodized oil is possible without development of hepatic
vascular injury in a case of relapse. We are currently conduct-
ing a phase III study of intra-arterial treatment with SM-11355
in comparison with conventional TACEwith epirubicin, which
is designed to detect the superiority of intra-arterial treatment
with SM-11355 in overall survival of TACE-naïve patients
with advanced HCC (Appendix).
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